Abstract 2070P
Background
Healthy lifestyle habits such as avoiding overweight, engaging in moderate physical activity for at least 150 minutes per week, and getting good quality sleep have not only been shown to decrease the incidence of certain cancers, but also have a clear impact on the outcome of patients diagnosed with breast cancer. Adherence to these recommendations has an impact on quality of life, and some studies suggest their beneficial effect on patient survival.
Methods
We included 181 patients diagnosed with breast cancer in different stages, Multivariable ambulatory circadian monitoring of skin temperature, motor activity, light exposure, and sleep patterns was performed for 7 consecutive days through a small watch-like device called Kronowise 3.0. The patients are divided into 3 groups: group 1 includes metastatic patients, group 2 consists of patients with early-stage breast cancer undergoing chemotherapy, and group 3 comprises patients with early-stage breast cancer under follow-up (more than 1 year after the completion of chemotherapy).
Results
The table describes the mean age with standard deviation, physical activity categorized as patients who achieve ≥ 150 minutes of moderate physical activity (MPA) per week, ≥ 300 minutes of moderate physical activity per week, ≥ 75 minutes of vigorous physical activity per week, patients with good sleep hygiene (between 7 and 9 hours of sleep per day), patients with < 10 hours of sedentary behavior, and the percentage of patients with overweight and obesity in each group. Table: 2070P
Median Age | MPA ≥ 150 min | MPA ≥ 300 min | Vigorous activity ≥ 75 min | Sedentariness < 10 hours | Median night sleep (hours) | Median BMI | BMI 25-30 | BMI ≥ 30 | |
GROUP 1 | 57 ± 9 | 65% | 45% | 4% | 90% | 7.5 | 25.53 | 21% | 20% |
GROUP 2 | 50 ± 7 | 88% | 73% | 15% | 100% | 6.7 | 23.26 | 15% | 5% |
GROUP 3 | 55 ± 10 | 89% | 79% | 20% | 100% | 6.5 | 26 | 20% | 17% |
Conclusions
Despite breast cancer patients not being sedentary and having higher levels of moderate physical activity compared to the general population, the occurrence of vigorous physical activity is quite low among these patients. It is imperative to establish proper sleep hygiene in these patients in order to improve parameters and reduce the rates of overweight and obesity, particularly among the metastatic population and long-term survivors, where these rates are significantly higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06